Weight‑loss Injection Health Risks
-
{
- All
- News
-
Wegovy Pill Users Lost Up To 21.6% Weight In New Obesity Trial
The findings come from Novo Nordisk's phase 3 OASIS 4 clinical trial studying oral semaglutide 25 mg, the same active ingredient used in injectable Wegovy.
-
Fake Mounjaro Worth Rs 56 Lakh Seized In Gurugram: What It Can Do To Your Body
Fake Mounjaro injections seized in Gurugram highlight rising counterfeit weight-loss drug risks and severe health dangers.
-
Popular Weight Loss Drugs May Lead To More Muscle Loss, Finds Study
The study analysed multiple studies and found that muscle-related tissue accounted for about 35% of total weight lost in incretin groups, exceeding safe benchmarks in two-thirds of cases.
-
Ozempic Might Preserve Lean Body Mass Better Than Mounjaro: Study
Both tirzepatide and semaglutide belong to a class of drugs that mimic hormones involved in appetite regulation. Semaglutide works by mimicking GLP-1, a hormone that helps control hunger and blood sugar levels.
-
Fake Weight Loss Injections Are Flooding The Market; Doctors Warn Patients Of Serious Health Risks
Fake weight loss injections are flooding the market, posing serious health risks. Dr Ravi Malik and Dr Shilpa Bhatte explain in depth about the prevalence of fake weight loss injections and how to safeguard yourself.
-
"Weight-Loss Injections Are Not For Wedding Prep Shortcut", Doctors Warn Against Misuse Of Ozempic, Mounjaro
These medications are designed for people with obesity or related health conditions, not for short-term aesthetic goals. When used by otherwise healthy individuals aiming for quick slimming, the balance between benefit and risk often becomes unfavour
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
Popular Weight Loss Drugs May Help Reduce Risk of Substance Use Disorders, Suggests New Study
A new study published in The BMJ says that GLP-1 drugs may help prevent and treat substance use disorders across all major addictive substances that were studied.
-
Stopping Weight-Loss Injections May Trigger Rapid Weight Regain: Oxford Study
A growing body of research shows that people who stop GLP-1 weight-loss injections such as Ozempic and Mounjaro often regain a significant portion of the weight within a year.
-
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, Extensior, in India
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
Ozempic Launched In India: Doctors Welcome New Diabetes Drug, Warn Against Misuse For Weight Loss
Doctors highlight that the drug should be administered along with a healthy diet and regular exercise for management of type 2 diabetes, and not just as cosmetic procedure for weight loss.
-
Wegovy Pill Users Lost Up To 21.6% Weight In New Obesity Trial
The findings come from Novo Nordisk's phase 3 OASIS 4 clinical trial studying oral semaglutide 25 mg, the same active ingredient used in injectable Wegovy.
-
Fake Mounjaro Worth Rs 56 Lakh Seized In Gurugram: What It Can Do To Your Body
Fake Mounjaro injections seized in Gurugram highlight rising counterfeit weight-loss drug risks and severe health dangers.
-
Popular Weight Loss Drugs May Lead To More Muscle Loss, Finds Study
The study analysed multiple studies and found that muscle-related tissue accounted for about 35% of total weight lost in incretin groups, exceeding safe benchmarks in two-thirds of cases.
-
Ozempic Might Preserve Lean Body Mass Better Than Mounjaro: Study
Both tirzepatide and semaglutide belong to a class of drugs that mimic hormones involved in appetite regulation. Semaglutide works by mimicking GLP-1, a hormone that helps control hunger and blood sugar levels.
-
Fake Weight Loss Injections Are Flooding The Market; Doctors Warn Patients Of Serious Health Risks
Fake weight loss injections are flooding the market, posing serious health risks. Dr Ravi Malik and Dr Shilpa Bhatte explain in depth about the prevalence of fake weight loss injections and how to safeguard yourself.
-
"Weight-Loss Injections Are Not For Wedding Prep Shortcut", Doctors Warn Against Misuse Of Ozempic, Mounjaro
These medications are designed for people with obesity or related health conditions, not for short-term aesthetic goals. When used by otherwise healthy individuals aiming for quick slimming, the balance between benefit and risk often becomes unfavour
-
How Semaglutide Works: Understanding Appetite, Hormones And Weight Loss In Simple Terms
Semaglutide belongs to a class of medicines that act on GLP-1 receptors, which play a major role in appetite, digestion and metabolism.
-
From Diabetes To Weight Loss: How Semaglutide Became The Blockbuster Behind Ozempic, Wegovy
From a diabetes drug to a global weight-loss phenomenon, semaglutide has reshaped modern medicine. As patents expire, cheaper versions may expand access, raising questions about affordability, safety and long-term impact.
-
Popular Weight Loss Drugs May Help Reduce Risk of Substance Use Disorders, Suggests New Study
A new study published in The BMJ says that GLP-1 drugs may help prevent and treat substance use disorders across all major addictive substances that were studied.
-
Stopping Weight-Loss Injections May Trigger Rapid Weight Regain: Oxford Study
A growing body of research shows that people who stop GLP-1 weight-loss injections such as Ozempic and Mounjaro often regain a significant portion of the weight within a year.
-
Abbott, Novo Nordisk India Partner Up To Launch Second Brand Of Ozempic, Widen Access To Diabetes Drug
Abbott has entered into a commercialisation agreement with Novo Nordisk India to market a second brand of semaglutide, Extensior, in India
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Novo Nordisk Sues Telehealth Company Over 'Knock-Off' Weight Loss Drugs, Flags Patient Safety Risks
The lawsuit, filed in the US, alleges that Hims infringed Novo Nordisk's patent by mass marketing compounded semaglutide products that have not been cleared by the US Food and Drug Administration (FDA).
-
Ozempic Launched In India: Doctors Welcome New Diabetes Drug, Warn Against Misuse For Weight Loss
Doctors highlight that the drug should be administered along with a healthy diet and regular exercise for management of type 2 diabetes, and not just as cosmetic procedure for weight loss.
